Multiple Traditional Chinese Medicine interventions for idiopathic pulmonary fibrosis

Abstract

Background: The therapeutic strategies of idiopathic pulmonary fibrosis (IPF) tend to be comprehensive. Improving the major symptoms and quality of life (QoL) is as important as postponing the process of fibrosis. However, only pirfenidone and nintedanib conditionally recommended by guidelines and no definite proof indicate that they can significantly ameliorate the main symptoms and QoL of IPF sufferers. At present, multiple types of Traditional Chinese Medicine (TCM) interventions alone or in combination with conventional western medicine managements are widespreadly applied in IPF treatment, which seemingly have a promising clinical effect, especially in ameliorating the main symptoms and improving QoL. Subsequently, the number of relevant studies in systematic reviews(SRs) and meta-analyses of randomized controlled trials(RCTs) increased significantly. Hence, we plan to implement an overview to collect, evaluate, and summarize the results of these SRs. Methods: An all-round literature retrieval will be conducted in 9 electronic databases, including PubMed, EMBASE, CINAHL, Cochrane Library, Epistemonikos, CNKI, CBM, Wanfang, and VIP. We will focus on the systematic review and meta-analysis of RCTs for multiple TCM interventions alone or in combination with routine western medicine measures in IPF treatment. The main outcomes we follow with interest include the improvement of major symptoms (cough, dyspnea) and QoL. Secondary outcomes will consist of minor symptoms improvement, clinical total effective rate, lung function, blood gas analysis, 6-minute walk text, adverse events, acute exacerbation, all-cause mortality, and IPF-related mortality. Two reviewers will independently select the SRs satisfactory with the enrolling criteria, extract key characteristics, and datas on predefined form, evaluate methodological quality by AMSTAR-2, ROBIS and PRISMA tools, and the quality of evidences adopting GRADE method. In case of any divergence will be reached an agreement by discussion or adjudicated by a third senior reviewer. We will perform a narrative synthesis of the proofs from SRs included. Results: The findings of this overvew will be presented at relevant conferences and submitted for peer-review publication. Conclusions: We expect to obtain comprehensive and reliable evidence of IPF treated by diversified TCM interventions from the potential standard SRs, which may provide suggestions for future RCTs and SRs. Registration number: INPLASY 202080110

Effectiveness and safety of acupoint application for chronic obstructive pulmonary disease

“…[ 20 ] In the stable period of disease, AA can stimulate the body's healthy qi, dredge the channels and collaterals, regulate qi and blood to enhance the body's antievil ability, and control the recurrence of disease. [ 21 ] This idea also fully embodies the concept of “treating pre-disease” in TCM. AA in the treatment of COPD is a typical application of this concept.…”

Effectiveness and safety of Chinese herbal formula combined with western medicine for ankylosing spondylitis

“…Meta-analysis can overcome the inadequacy of traditional literature reviews and provide a quantitative synthesis, which can provide a systematic, reproducible, and objective synthesis method for the question. In addition, meta-analysis has the advantages of increasing test power, increasing study precision, answering questions not posed by a single study, resolving controversies arising from conflicting findings, or generating new hypotheses [28] . Therefore, we will implement a systematic review and meta-analysis to synthesize clinical trials of CHFs combined with western medicine for AS treatment, and conduct a quantitative synthesis to evaluate its efficacy and safety.…”

Efficacy and safety of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis caused by novel coronavirus disease

“…[ 11 ] In recent years, traditional Chinese medicine (TCM) has made great progress in the treatment of pulmonary fibrosis, to some extent making up for the shortage of Western medical treatment. [ 12 ] It can be symptomatic in patients according to different population constitution, different disease course, and according to different geographical, climate, environment and other factors, it has the advantage of individualization, its efficacy is significant, side effects are small, and the mechanism of action involves several pathways and targets, which has shown significant advantages in the battle against COVID-19, effectively blocking disease progression, Promote patient recovery. [ 13 ] The treatment protocol of COVID-19 was also introduced in the new diagnosis and treatment protocol for coronavirus pneumonia (Trial VI Edition), in which the total effective rate of Qingfei detoxification decoction was 97%.…”

“…For the treatment of pulmonary fibrosis, glucocorticoids, antacid preparations, and immunosuppressive agents are commonly used in Western Medicine, [10] and so far, only pirfenidone and nintedanib have been approved by FDA, but their efficacy is not ideal and they have some side effects [11] . In recent years, traditional Chinese medicine (TCM) has made great progress in the treatment of pulmonary fibrosis, to some extent making up for the shortage of Western medical treatment [12] . It can be symptomatic in patients according to different population constitution, different disease course, and according to different geographical, climate, environment and other factors, it has the advantage of individualization, its efficacy is significant, side effects are small, and the mechanism of action involves several pathways and targets, which has shown significant advantages in the battle against COVID-19, effectively blocking disease progression, Promote patient recovery [13] .…”